AzTrials
AzTrials

Covid19NCT04595240

Semen Analysis Changes in Covid-19 Positivepatients

An observational study of Covid19, run by Assiut University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The viral pandemic of the coronavirus disease 2019 (COVID-19), generated by a novel mutated severe acute respiratory syndrome coronavirus (SARS-CoV-2), has become a serious worldwide public health emergency, evolving exponentially. Read more about this study

Who is it for?
Ages 20 to 45 years, men onlyHealthy volunteers can take part
Conditions the study is for
Covid19
What is being tested?
semen analysis
How many people
100 participants
Where
1 siteEgypt
Study dates
1 May 2020to 15 Oct 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Study population: men with th mentioned criteria

Who may be able to join

  • adult male patient age younger than 45 years old
  • no history of fertility disorders
  • good body built and secondary sexual charcter .

Who cannot join

  • congenital anomalies of the testis
  • chronically ill patients
  • proplems of male fertility
  • males with varicocele
  • sexual performance disorders .

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Mostafa Kamel

    Asyut, 71511

Other trials in Egypt

About this study

Official title: Semen Analysis Changes in Covid-19 Positive Patients

The viral pandemic of the coronavirus disease 2019 (COVID-19), generated by a novel mutated severe acute respiratory syndrome coronavirus (SARS-CoV-2), has become a serious worldwide public health emergency, evolving exponentially. While the main organ targeted in this disease is the lungs, other vital organs, such as the heart and kidney, may be implicated. The main host receptor of the SARS-CoV-2 is angiotensin converting enzyme 2 (ACE2), a major component of the renin-angiotensin-aldosterone system (RAAS). The ACE2 is also involved in testicular male regulation of steroidogenesis and spermatogenesis. As the SARS-CoV-2 may have the potential to infect the testis via ACE2 and adversely affect male reproductive system.

Read the detailed description

A recent report published in JAMA Network Open revealed that in an analysis 38 semen samples from COVID-19 patients, 6 (four at the acute stage of infection and, alarmingly, two who were recovering) tested positive for the virus by RT-PCR.

Importantly, at this point, the investigators have no idea whether the actual virus was viable and infectious. Nevertheless, the possibility that this coronavirus could have a pathophysiological impact on the testes was suggested by additional data indicating that active COVID-19 infection dramatically reduced the testosterone-to-LH ratio, suggesting a significant impact on the responsiveness of Leydig cells to LH stimulation In many ways, the investigators should not be surprised by these observations because the blood-testes barrier is known to offer little defense against viral invasion, given the wide range of pathogenic viruses (HIV, hepatitis, mumps, papilloma) that are known to be capable of damaging the testes and rendering the host infertile.

The angiotensin system plays a critical role in the survival and functionality of human spermatozoa but also creates a vulnerability to COVID-19 attack. Angiotensin 1 is a biologically inactive decapeptide that is cleaved by ACE1 to create angiotensin II, which in turn activates the AT1R and AG2R receptors, both of which are present in these cells. Angiotensin II is further processed by ACE2 to generate angiotensin 1-7 which binds the MAS receptor activating PI3K. The latter then phosphorylates AKT, which maintains cell viability by phosphorylating key regulators of sperm apoptosis such as BAD. As long as BAD is phosphorylated, it is held in abeyance by a 14-3-3 keeper protein. However, if the PI3/AKT pathway becomes compromised, BAD dephosphorylates, is released from its association with 14-3-3, and moves to the mitochondria where it inactivates anti-apoptotic factors and promotes the intrinsic apoptotic cascade. The spike protein on COVID-19 specifically targets ACE2 and in so doing removes an important stimulus for PI3K/AKT, thereby compromising sperm viability. Subsequent to COVID-19 binding, the ectodomain of ACE2 may be removed by ADAM proteases and shed from the sperm surface. Alternatively proteases from the TMPRSS-family, either as intrinsic components of the sperm plasma membrane or delivered by seminal prostasomes, can facilitate fusion between the virus and the sperm surface by cleaving ACE2 and the viral spike proteins (S1 and S2) at the sites indicated by dashed lines, thereby completing the transformation of this cell from procreating gamete to viral vector.

An additional concern of the COVID-19 pandemic that might impact male fertility is fever. Particularly high and sustained elevation in body temperature is a major manifestation of the COVID-19 pandemic, which complicates more than 80% of patients. The concept that fever and elevation of testicular temperature result in impairment of spermatogenesis is widely accepted.

More importantly, emerging evidence indicates that a subgroup of patients with severe COVID-19 might have a secondary cytokine storm syndrome (hemophagocytic lymphohistiocytosis). This is an underrecognized, hyperinflammatory syndrome characterized by sustained fever, with fulminant and fatal hypercytokinemia with multiorgan failure. These patients have a particular serum blood cytokine profile with cytopenia and hyperferritinemia. These findings also suggest that immunomodulatory therapy (IL-6 antagonist) may improve mortality rate considerably in these patients.

As cytokines contribute to testicular function and maintenance of male reproductive health, and to the pathologies associated with their abnormal activity in this organ, COVID-19-induced changes in cytokines profile may have further implications to male fertility. In addition, immunomodulatory therapies may provoke potential long-term effects on male fertility and are a matter of concern. Furthermore, cytokine microenvironment deviations within the testis may have tumorigenic adverse effects on the cellular level, leading eventually to testicular cancer, a second long-term matter of concern.

Aim of the study :

Know the Effect of covid-19 on spermatogenesis

Conditions
Covid19
Being tested
semen analysis
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • semen analysisDiagnostic test

    semen analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. changes of semen volume in (ML)by covid-19 from normal values.

    semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis

    Measured: 72days after infection

  2. changes of sperm concentration in (million/ml) by covid-19 from normal values.

    semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis

    Measured: 72days after infection

  3. changes of sperm morphology in (percentage of normal forms) by covid-19 from normal values.

    semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis

    Measured: 72days after infection

  4. changes of sperm motility in percentage of (A+B) by covid-19 from normal values.

    semen analysis taken by 72day of infection to see the effect on the new cycle of spermatogenesis

    Measured: 72days after infection

  5. changes of semen volume in (ML) by covid-19 from from the first sample

    semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.

    Measured: after 72 days of the first sample

  6. changes of sperm concentration in (million /ML) by covid-19 from from the first sample

    semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.

    Measured: after 72 days of the first sample

  7. changes of sperm morphology in percentage of normal form by covid-19 from from the first sample

    semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.

    Measured: after 72 days of the first sample

  8. changes of sperm motility in percentage of (A+B) by covid-19 from from the first sample

    semen analysis taken by 72day of the first negative swab of covid-19 to see the effect on the new cycle of spermatogenesisand to compare with the first sample which done during infection.

    Measured: after 72 days of the first sample

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2020
  2. Study start1 May 2020
  3. Primary completion15 Oct 2020
  4. Study completion15 Oct 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04595240
Sponsor's protocol ID
Semen analysis post covid-19
Status last verified
Oct 2020
First submitted
14 Oct 2020
Last updated
20 Oct 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Mohammed N, Kamel M, Gadelkareem RA, Zarzour MA, Kurkar A, Abdel-Moniem AM, Behnsawy H. Semen quality changes during infection and recovery phases of mild-to-moderate COVID-19 in reproductive-aged patients: a prospective case series. Basic Clin Androl. 2023 Jan 19;33(1):2. doi: 10.1186/s12610-022-00175-7.

    PubMed 36653786

Questions about this trial

What is this clinical trial studying?

An observational study of Covid19, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

changes of semen volume in (ML)by covid-19 from normal values. (time frame: 72days after infection). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04595240, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Semen Analysis Changes in Covid-19 Positivepatients | AzTrials